Cargando…
Evaluating Human Papillomavirus Vaccination Programs
Human papillomavirus (HPV) has been implicated as the primary etiologic agent of cervical cancer. Potential vaccines against high-risk HPV types are in clinical trials. We evaluated vaccination programs with a vaccine against HPV-16 and HPV-18. We developed disease transmission models that estimated...
Autores principales: | Taira, Al V., Neukermans, Christopher P., Sanders, Gillian D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3328990/ https://www.ncbi.nlm.nih.gov/pubmed/15550200 http://dx.doi.org/10.3201/eid1011.040222 |
Ejemplares similares
-
Cost Effectiveness of a Potential Vaccine for Human papillomavirus
por: Sanders, Gillian D., et al.
Publicado: (2003) -
Evaluating human papillomavirus vaccination programs in Canada: should provincial healthcare pay for voluntary adult vaccination?
por: Llamazares, Marco, et al.
Publicado: (2008) -
Ethical issues related to human papillomavirus vaccination programs: an example from Bangladesh
por: Salwa, Marium, et al.
Publicado: (2018) -
Economic evaluation of human papillomavirus vaccination in the United Kingdom
por: Jit, Mark, et al.
Publicado: (2008) -
Discrepancies in the evaluation of the safety of the human papillomavirus vaccine
por: Cervantes, Jorge L, et al.
Publicado: (2018)